Novartis AG (NVS)

86.16
NYSE : Health Care
Prev Close 84.94
Day Low/High 85.85 / 86.34
52 Wk Low/High 66.93 / 86.90
Avg Volume 1.56M
Exchange NYSE
Shares Outstanding 2.34B
Market Cap 199.01B
EPS 2.80
P/E Ratio 30.12
Div & Yield 2.72 (3.20%)

Latest News

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis' CAR-T Gene Therapy Receives FDA Approval

The treatment is the first of its kind to be authorized in the U.S.

StoneMor Shares Have Fallen Like a Stone

But even at this low level, the stock is no bargain.

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

Jim Cramer is bullish on Novartis AG, Sirius XM Radio, Coupa Software and Juno Therapeutics.

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.

European Pharma Companies Slip on MS Pricing Probe

European Pharma Companies Slip on MS Pricing Probe

House Democrats start probe into MS drug prices

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Regrets? One Was Slow Top-Line Growth, Says Outgoing Mondelez CEO

Regrets? One Was Slow Top-Line Growth, Says Outgoing Mondelez CEO

Dirk Van de Put of McCain Foods is the snack company's new CEO, starting in November.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are slightly higher on Tuesday, following the collapse of healthcare overhaul in the U.S.

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European stocks are firmly on the back foot.

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis sees stronger full-year Alcon sales

Netflix, Microsoft Better Blow Everyone Away With Their Earnings This Week, Or Else

Netflix, Microsoft Better Blow Everyone Away With Their Earnings This Week, Or Else

The second-quarter earnings season picks up speed.

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.

Novartis Secures FDA Panel's Approval for Cutting Edge Cancer Drug

Novartis Secures FDA Panel's Approval for Cutting Edge Cancer Drug

The panel voted 10-0 that the drug, tisagenlecleucel, should be approved to treat patients with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of U.S. childhood cancer.

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.

FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite Pharma

FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite Pharma

Investment firm Canaccord Genuity believes Kite Pharma is poised to take advantage of the positive results from Novartis' experimental gene therapy drug.

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Tech, healthcare slide weighs on rest of markets.

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Healthcare's slide weighs on rest of markets.

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide

Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide

Futures lower even as crude oil rises.

Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success

Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success

Novartis shares led gainers in Switzerland Thursday after the pharmaceuticals group told investors that its Canakinumab drug met its primary endpoint in phase three clinical trials.

TheStreet Quant Rating: B (Buy)